Pharmaceutical News

• Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupr ...
  Thu, 02 September 2010
  Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just si ...
• Therapeutic Workshops To Highlight Opportunities In Biotech At 9th Annual BIO Investor Forum
  Thu, 02 September 2010
  BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum - a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies...
• Roche Provides Update On FDA Application For T-DM1
  Thu, 02 September 2010
  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study...
• Novartis Drug Tasigna Approved In Switzerland After Fast-track Review For Treatment Of P ...
  Thu, 02 September 2010
  The Swiss health authority Swissmedic has granted approval for Tasigna (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph CML) in chronic phase...
• BRINAVESS? (vernakalant) For Infusion Approved In The European Union For Rapid Conversio ...
  Thu, 02 September 2010
  Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp...
• Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Ant ...
  Thu, 02 September 2010
  Eisai Co., Ltd. (Headquarters: Tokyo, Japan, President & CEO: Haruo Naito, Eisai) announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease...
• Actavis Receives FDA Approval Of Atomoxetine HCl Capsules
  Thu, 02 September 2010
  Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD). Actavis intends to market Atomoxetine HCl in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg strengths...
• Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive ...
  Thu, 02 September 2010
  ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its pri ...
• ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By Mor ...
  Thu, 02 September 2010
  ReVision Therapeutics Inc. announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration (AM ...
• Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
  Thu, 02 September 2010
  A recent study conducted by oculoplastic surgeon Charles Soparkar, M.D., Ph.D. (The Methodist Hospital, Houston, TX) utilizing a patent-pending formulation of zinc and phytase (trademarked as ZYTAZE?), demonstrated that increasing zinc levels by oral administration for 4 days prior to a planned injection of botulinum toxin i ...